Reimbursed Care Access in Nepal

Currently classified under Nepal’s broad narcotics control framework and not available for routine medical use. The Narcotic Drugs (Control) Act, 2033 (1976) prohibits unauthorised cultivation, production, distribution, import, export and consumption of narcotic drugs; substances not specifically licensed for medicinal or research use fall under the Act’s prohibition and require formal authorisation for any legal medical or research activity. #. Currently there is no authorised, reimbursed clinical psilocybin program or national regulatory approval for psilocybin-based therapies in Nepal; access is therefore limited to formally authorised research only (if and when approved by Nepalese authorities), otherwise possession/use is treated as a narcotics offence under the Act.

Currently classified as a strictly controlled substance under Nepal’s Narcotic Drugs (Control) Act, 2033 (1976), with no authorised medical use or national reimbursement pathway outside of approved, formally authorised clinical research. #. There is no publicly documented MDMA medical program or licenced therapeutic supply chain in Nepal.

Esketamine (intranasal esketamine, e.g., Spravato) is not documented as an approved, reimbursed product in Nepal’s public essential medicines and does not appear on Nepal’s national essential medicines lists or in publicly available registers as a marketed, reimbursed psychiatric treatment. By contrast, the Department of Drug Administration / national essential medicines documents list conventional ketamine for anaesthetic use, but there is no evidence of registered esketamine marketing authorisation or a national reimbursement pathway for esketamine-based depression treatment in Nepal. [National List of Essential Medicines NEPAL (ketamine listed) — Government of Nepal Ministry of Health / Department of Drug Administration; see ketamine listing]. Access in Nepal for esketamine would therefore be limited (absent a local marketing authorisation) to import under special licence or authorised research, neither of which represents routine reimbursed care.

Ketamine is an established, licenced injectable anaesthetic and analgesic in Nepal and is explicitly listed on Nepal’s National List of Essential Medicines (injectable ketamine 50 mg/ml). #.

Regulatory & clinical context: Ketamine is registered and marketed in Nepal (multiple commercial ketamine brands are available in the domestic market), is used routinely across public and private hospitals as an anaesthetic and analgesic, and is procured under government essential‑medicines procurement channels. Examples of local product listings and brand information show ketamine formulations available for clinical use in Nepal. #.

Reimbursement / access nuances: Nepal’s public health system maintains a list of free essential medicines that central and local governments procure and distribute to state-run facilities; ketamine appears on the national essential medicines list used to guide procurement and hospital supply. However, the practical availability of even listed essential medicines varies by facility and locality and many patients still face out‑of‑pocket costs or stockouts in practice (government lists of ‘free essential medicines’ exist but supply gaps have been reported). Thus, while ketamine is nationally recognised and procured for clinical use (including in public hospitals), the patient financial burden depends on facility-level availability and the local procurement/distribution situation rather than a guaranteed nationwide outpatient reimbursement program. #; #.

Currently classified as a strictly controlled substance under Nepal’s Narcotic Drugs (Control) Act, 2033 (1976) with no authorised medical market or reimbursement framework; no routine clinical use is permitted outside of formally authorised research. #.

Currently classified as a strictly controlled substance under Nepal’s narcotics framework with no authorised medical use or reimbursement pathway; possession and distribution are subject to the prohibitions of the Narcotic Drugs (Control) Act absent a specific license for research or government-authorised medicinal import. #.

Currently classified as a strictly controlled substance under Nepal’s narcotics law with no authorised medical program or reimbursement pathway in Nepal; access is only conceivable via formally authorised research approvals and not via routine clinical care. #.

Ayahuasca preparations contain DMT and are treated under Nepal’s narcotics control regime; there is no authorised clinical or reimbursed pathway for ayahuasca use in Nepal and it would be subject to the Narcotic Drugs (Control) Act unless specifically authorised for approved research. #.

Mescaline is not available for authorised medical treatment or reimbursement in Nepal and falls under the country’s narcotics prohibitions; there is no routine clinical access or insurance reimbursement pathway. Any lawful medical or research use would require specific government licensing under the Narcotic Drugs (Control) Act. #.

2C‑series compounds (so‑called 2C‑X designer phenethylamines) are treated as controlled/illicit under Nepal’s narcotics framework with no authorised medical use or reimbursement; there is no legal pathway for routine therapeutic use in Nepal outside of formally approved, licensed research. #.